Priced for one buyer, wanted by many: management describes new sources of demand converging on the same thing it already
The model's full reasoning — Q3 2021 call → NOWe need to determine if the transcript describes a widening demand base for an existing product, with management responding to the convergence, and the numbers lagging. The company is Akebia, with products Auryxia (for hyperphosphatemia) and vadadustat (investigational, not yet approved). The call is about Q3 2021. The main focus is on vadadustat, which is not yet approved. The question asks about "the same thing the company already makes or does" - so it must be an existing product. Auryxia is the existing commercial product. Vadadustat is not yet approved, so any demand for it is prospective, not current. The transcript discusses vadadustat's potential launch, but that's future. The question specifically asks about demand for existing offering. Auryxia is the existing product. Is there any mention of widening demand for Auryxia? The transcript mentions Auryxia revenue growth, but that's due to higher net revenue per pill and payer mix, not new sources of demand. No mention of new applications, new geographies, new customer types for Auryxia. The discussion about vadadustat is about a product not yet approved, so it's not existing. Also, the question asks about "the same thing the company already makes" - vadadustat is not yet made/sold. So the answer is NO. Even if we consider vadadustat, it's not approved, so demand is not real. The transcript says "vadadustat is not yet approved" and discussions are about potential. So no. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
LINC · Q1 2024 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with specific criteria. YES Management describes the core offering—curriculum and training capabilities already in place—as now being applied in a new direction: B2B corporate upskilling contracts (e.g., the CMC agreement) alongside campus-based student programs. They explicitly state they are pursuing additional employer contracts and expanding corporate partnerships, with the new 5-year, $6 million CMC deal representing real, recent revenue that contributed nothing to the reported quarter and is still ramping up through site setup and staffing. This meets all three criteria as a single coherent development.
OPAD · Q3 2023 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with specific criteria. YES The transcript shows management describing demand for renovations (already part of their core iBuyer operations) now coming from multiple directions: their own inventory, third-party B2B clients (nearly 50 clients, 127% increase in closed projects), and soon homeowners via Rental Captain.
PFIE · Q1 2023 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with the demand base widening recently, and manageme...